

**INNOVATIVE APPROACHES TOWARDS DEVELOPMENT AND  
UTILIZATION OF DNA DIAGNOSTICS FOR *Salmonella* Typhi**

**by**

**AZIAH BINTI ISMAIL**

**Thesis submitted in fulfilment of the  
Requirements for the degree of  
Doctor of Philosophy**

**January 2009**

## ACKNOWLEDGEMENT

This thesis is the end of my long journey in obtaining my PhD at Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia (USM). I would like to express my gratitude to all who had given me the possibility to complete this thesis. I am deeply indebted to my supervisor Professor Asma Ismail whose help, stimulating suggestions and encouragement led me throughout this research and writing of this thesis. Her vast knowledge and logical way of thinking have been of great value to me. Her understanding, encouraging and personal guidance had provided me a good basis for the present thesis. I am also deeply grateful to my co-supervisor, Professor M. Ravichandran, for his detailed and constructive comments, as well as his support throughout this work.

During this work I collaborated with many colleagues for whom I have great regard, and I wish to extend my warmest thanks to all who had helped me in Genomic and Proteomic laboratories, INFORMM. I would like to thank Dr. Lee Su Yin and Professor Mohd Zaki Salleh who looked closely at the final version of the thesis for grammatical error, both correcting and offering suggestions for improvement.

I would also like to thank USM and JPA/MOHE for awarding me the ASTS Fellowship, which has supported me during my four years of study. I wish to thank all the lecturers, administration and R&D staff for helping me to get through the difficult times, and the emotional support, entertainment, and care they provided.

I cannot end without thanking my family, whose constant encouragement and love I have relied throughout my time at INFORMM. Special thanks to my husband for his patience and love which enabled me to complete this work. Your patience, love and

encouragement had upheld me, particularly in those many days which I spent more time with my lab work and my computer than with you. I wish to thank my mother, my late father, my mother-in-law, my brothers and my sisters for providing me a loving environment.

This research was supported by the National Biotechnology Division (NBD) Topdown Grant, Ministry of Science, Technology and Innovation, Malaysia and the USM Research University Grant. I would also like to thank the Department of Microbiology, Kota Bharu Hospital, Kelantan, Malaysia; the Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia Hospital, Kelantan, Malaysia and Institute Biological Sciences, Universiti Malaya, Kuala Lumpur, Malaysia for their invaluable help in donating the pure cultures of *S. Typhi* and other organisms.

## TABLES OF CONTENTS

<b>ACKNOWLEDGEMENT</b> .....	ii
<b>TABLES OF CONTENTS</b> .....	iv
<b>TABLES OF CONTENTS</b> .....	xii
<b>LIST OF FIGURES</b> .....	xiv
<b>LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS</b> .....	xvii
<b>ABSTRAK</b> .....	xx
<b>ABSTRACT</b> .....	xxiii
<b>CHAPTER 1</b>	
<b>General Introduction</b> .....	1
1.1 Introduction to typhoid fever .....	1
1.2 Characteristics of <i>S. Typhi</i> .....	2
1.3 Global epidemiology of typhoid fever .....	3
1.4 Epidemiology of typhoid in Malaysia .....	7
1.5 Mode of transmission of typhoid .....	8
1.6 Treatment of typhoid fever .....	9
1.7 Management of typhoid carriers .....	12
1.8 Definition of typhoid fever and typhoid carrier .....	12
1.9 Diagnosis of typhoid fever .....	14
1.9.1 Culture method .....	14
1.9.2 Felix-Widal test .....	15
1.9.3 Tubex test .....	16
1.9.4 TYPHIDOT and TYPHIDOT –M .....	16
1.10 Diagnosis of typhoid carriers .....	17
1.11 Research background and rationale of the study .....	19
1.11.1 History of 50 kDa outer membrane protein of <i>Salmonella Typhi</i>	19
1.11.2 Development of molecular methods for detection of <i>S. Typhi</i> from blood, stool and rectal swab .....	20

## CHAPTER 2

### The usefulness of gene encoding for outer membrane protein of *Salmonella* Typhi (ST50) in PCR assay for the rapid detection of *S. Typhi*

2.1	Introduction .....	27
2.1.1	Specific objectives of the study .....	28
2.2	Materials and methods .....	31
2.2.1	Bacterial strains .....	31
2.2.2	Extraction of DNA from pure bacterial cultures .....	31
2.2.3	Design of PCR primers .....	31
2.2.4	Amplification of ST50 gene for the identification of <i>S. Typhi</i> .....	32
2.2.4.1	Optimization of the annealing temperature and MgCl <sub>2</sub> concentration .....	32
2.2.4.2	Evaluation of PCR assay .....	32
2.2.4.3	Detection and confirmation of PCR product .....	33
2.2.4.4	Analytical sensitivity of amplification .....	33
2.2.4.5	Evaluation of sensitivity and specificity of the PCR assay .....	34
2.2.5	Amplification of ST50 gene for identification of <i>S. Typhi</i> in the presence of IAC .....	34
2.2.5.1	Determination of IAC concentration .....	34
2.2.5.2	Optimization of the MgCl <sub>2</sub> concentration .....	35
2.2.5.3	Amplification of targeted gene and IAC DNA .....	35
2.2.5.4	Analytical sensitivity of amplification .....	35
2.2.5.5	Evaluation of sensitivity and specificity of the PCR assay .....	35
2.3	Results .....	38
2.3.1	Primer design .....	38
2.3.2	Amplification of ST50 gene for identification of <i>S. Typhi</i> .....	38
2.3.3	Amplification of ST50 gene for identification of <i>S. Typhi</i> in the presence of internal amplification control (IAC) .....	39
2.4	Discussion .....	50

## CHAPTER 3

### Development and utilization of a dry-reagent-based PCR assay for the detection of *Salmonella* Typhi in BACTEC blood cultures

3.1	Introduction .....	53
3.2	Materials and methods .....	56
3.2.1	Blood cultures .....	56

3.2.2	Preparation of DNA from BACTEC blood culture broths .....	56
3.2.3	Preparation of dry-reagent-based PCR.....	57
3.2.4	Amplification of DNA extracted from BACTEC blood culture broths .....	57
3.2.5	Evaluation of the PCR .....	58
3.3	Results .....	58
3.4	Discussion .....	68

## **CHAPTER 4**

### **Stability testing and comparison of reproducibility and consistency of the dry reagent based PCR**

4.1	Introduction .....	71
4.1.1	Specific objectives of the study .....	72
4.2	Materials and methods .....	72
4.2.1	Bacterial strains .....	72
4.2.2	DNA extraction procedure from pure culture .....	75
4.2.3	Stability testing of the dry-reagent based PCR .....	75
4.2.4	Comparison of reproducibility and consistency of the dry reagent based PCR .....	75
4.3	Results .....	76
4.3.1	Efficiency of the dry-reagent-based PCR .....	76
4.3.2	Comparison of reproducibility and consistency of the dry reagent based PCR .....	82
4.4	Discussion .....	85

## **CHAPTER 5**

### **The use of dry-reagent-based PCR for the detection of *Salmonella Typhi* in stool and rectal swab culture specimens of suspected carriers**

5.1	Introduction .....	87
5.1.1	The specific objectives of the study .....	89
5.2	Optimization of DNA extraction from stool cultures and evaluation of the sensitivity and specificity of PCR assay from spiked stool cultures....	90
5.2.1	Materials and methods .....	90
5.2.1.1	Bacterial strain .....	90
5.2.1.2	Collection of stool sample .....	92
5.2.1.3	Preparation of serial dilution of <i>S. Typhi</i> .....	92
5.2.1.4	Preparation of DNA extraction method .....	92
5.2.1.4.1	Addition of PVP solution in stool suspension	92

	5.2.1.4.2	Addition of PVP solution in washing step ...	93
	5.2.1.4.3	Without the addition of PVP in both stool suspension and washing step .....	94
	5.2.1.5	Amplification of ST50 gene using the extracted DNA ...	94
	5.2.1.6	Preparation of stool suspension and spiking with <i>S. Typhi</i>	95
	5.2.2	Results .....	95
	5.2.3	Discussion .....	102
5.3		Comparative efficacy of PCR assays using stool and rectal swab cultures	104
	5.3.1	Materials and methods .....	104
	5.3.1.1	Serial dilution of the overnight culture .....	104
	5.3.1.2	Stool specimen .....	104
	5.3.1.3	Rectal swab specimen .....	104
	5.3.1.4	Enrichment of spiked stool suspension .....	106
	5.3.1.5	Enrichment of spiked rectal swab suspension .....	106
	5.3.1.6	DNA extraction from the enrichment culture .....	106
	5.3.1.7	PCR assay .....	106
	5.3.2	Results .....	107
	5.3.2.1	Spiked stool cultures at 37°C .....	107
	5.3.2.2	Spiked stool cultures at room temperature .....	107
	5.3.2.3	Spiked rectal swab cultures at 37°C .....	108
	5.3.2.4	Spiked rectal swab cultures at room temperature .....	108
	5.3.3	Discussion .....	110
5.4		The use of PCR for the detection of <i>S. Typhi</i> from stool samples .....	114
	5.4.1	Materials and methods .....	114
	5.4.1.1	<i>S. Typhi</i> strain and culture conditions .....	114
	5.4.1.2	Collection of stool samples .....	114
	5.4.1.3	Stool sampling by fixed weight .....	115
	5.4.1.4	DNA extraction .....	117
	5.4.1.5	Amplification procedure .....	117
	5.4.2	Results .....	118
	5.4.2.1	Cultures of stools spiked with <i>S. Typhi</i> .....	118
	5.4.2.2	Cultures of stools from possible carriers.....	120
	5.4.3	Discussion .....	122

## CHAPTER 6

### General discussion, conclusions and future directions

6.1	General discussion and conclusions .....	126
6.1.1	Benefits of the current research project .....	128
6.2	Future directions .....	129
6.2.1	Further improvements on the currently developed dry-reagent-based PCR .....	129
6.2.2	Improving the detection method for the PCR product .....	130
6.2.3	Development of a real-time PCR assay for mass screening of typhoid carriers .....	131
6.2.4	Development of multiplex PCR for <i>S. Typhi</i> , <i>S. Paratyphi A</i> , <i>B</i> and <i>C</i> and, other <i>Salmonella</i> serotypes .....	131
6.2.5	Characterization of 50 kDa outer membrane protein of <i>S. Typhi</i> .....	132

<b>REFERENCES</b> .....	133
-------------------------	-----

<b>APPENDICES</b> .....	143
-------------------------	-----

Appendix A1 .....	143
A1.1 Source of bacterial strains/isolates .....	143
A1.2 Source of bacterial strains for transformation of plasmid pVCHMII .....	143
A1.3 Plasmid .....	144
A1.3.1 pVCHMII .....	144
A1.3 Storage of bacterial culture in liquid media (Sambrook and Russel, 2001) .....	145
Appendix A2 .....	146
A2.1 Media and chemicals .....	146
A2.2 Commercial kits and reagents .....	147
A2.3 Molecular weight markers .....	148
A2.3.1 1kb DNA ladder (Promega, USA) .....	148
A2.3.2 Lambda DNA/ <i>Hind</i> III (Promega, USA) .....	148
A2.4 PCR reagents .....	148
A2.4.1 Primers .....	148
A2.4.2 <i>Taq</i> DNA polymerase, buffer and MgCl <sub>2</sub> (Promega)...	150
A2.4.3 PCR nucleotide mix (Promega) .....	150
Appendix 3 .....	151
A3.1 Preparation of media .....	151



A3.1.1	Nutrient broth .....	151
A3.1.2	Nutrient agar .....	151
A3.1.3	LB broth .....	151
A3.1.4	LB agar .....	152
A3.1.5	Selenite-F broth .....	152
A3.1.6	MacConkey No 2 agar .....	152
A3.1.7	MacConkey No 3 agar .....	153
A3.1.8	Blood agar .....	153
A3.1.9	Triple Sugar Iron (TSI) agar .....	153
A3.1.10	Desoxycholate citrate agar (DCA) .....	153
A3.1.11	MRVP medium .....	154
A3.1.12	SIM medium .....	154
A3.1.13	Urea agar base .....	154
A3.1.14	Simmons citrate agar .....	155
A3.1.15	Cary-Blair medium .....	155
Appendix A4	.....	156
A4.1	Buffers and solutions .....	156
A4.1.1	Phosphate buffered saline .....	156
A4.1.2	Normal saline (0.9% sodium chloride solution) .....	156
A4.1.3	0.5 M EDTA .....	156
A4.1.4	Tris-HCl 10 mM (pH 8.0) .....	156
A4.1.5	Orange G loading dye .....	157
A4.1.6	5% Polyvinyl pyrrolidone (PVP) .....	157
A4.1.7	3M NaOH .....	157
A4.1.8	Ampicillin stock solution 100 mg/ml .....	157
A4.1.9	50× Tris-Acetate EDTA (TAE) buffer .....	158
A4.1.10	Ethidium bromide (10 mg/ml) .....	158
A4.2	Bioinformatic tools .....	158
A4.2.1	Primer design for the target gene .....	158
A4.2.2	Primer for the internal amplification control .....	159
A4.3	Polymerase chain reaction (PCR) .....	159
A4.3.1	Preparation of primers stock solutions (100 pmol/μl) ..	159
A4.3.2	Preparation of primer working solutions (10 pmol/μl)..	160
A4.3.3	Preparation of PCR reaction mixture .....	160
A4.3.4	Cycling condition for polymerase chain reaction .....	161
A4.4	Agarose gel electrophoresis .....	161

A4.4.1	Preparation of 50× TAE .....	161
A4.4.2	Preparation of 1% agarose gel .....	161
A4.4.3	Agarose gel electrophoresis .....	162
A4.4.4	Decontamination of electrophoresis buffer containing 0.5 µg/ml ethidium bromide (Sambrook and Russel, 2003) .....	163
A4.5	DNA Extraction .....	163
A4.5.1	Genomic DNA extraction protocol using “DNeasy® Tissue Kits” (Qiagen, USA) .....	163
A4.5.2	Determination of concentration and purity of DNA using spectrophotometer .....	164
A4.5.3	Genomic DNA extraction using boiling method .....	165
A4.5.4	Plasmid DNA extraction protocol using “Plasmid DNA kit” (Qiagen) .....	165
A4.5.5	Plate count of pure culture suspension by spread method .....	167
A4.5.5.1	Dilution of cell suspension before plating ..	167
A4.5.5.2	Spread-plate method of performing a viable count .....	167
A4.5.5.3	Calculating the number of bacteria per ml of serially diluted bacteria .....	167
A4.6	DNA sequencing .....	168
A4.6.1	Procedures of purification of PCR product .....	168
A4.6.2	Preparation of sequencing reactions .....	169
A4.6.3	Cycle sequencing .....	169
A4.6.4	Purification using ethanol/EDTA precipitation method	169

**LIST OF PUBLICATIONS, PRESENTATIONS, AWARDS AND  
COURSES ATTENDED**

1.	Publications .....	170
2.	Research presentations .....	170
2.1	Oral presentations .....	170
Presentation 1	.....	170
Presentation 2	.....	170
Presentation 3	.....	171
Presentation 4	.....	171

	Presentation 5 .....	171
	Presentation 6 .....	171
	Presentation 7 .....	171
	Presentation 8 .....	171
	Presentation 9 .....	171
	Presentation 10 .....	172
2.2	Poster presentations .....	172
	Presentation 1 .....	172
	Presentation 2 .....	172
	Presentation 3 .....	172
3.	Awards .....	172
3.1	National/International .....	172
	Anugerah Inovasi Negara 2006 - Kategori Inovasi	
	Produk .....	172
	Silver Medal .....	173
	Gold Medal .....	173
	Best Invention in Biotechnology .....	173
3.2	Universiti Sains Malaysia .....	173
	Hadiah Sanjungan 2007 (Kategori Penerbitan) .....	173
	Hadiah Sanjungan 2006 (Kategori Produk Penyelidikan)	173
	Anugerah Sanggar Sanjung 2005 (Kategori Produk	
	Penyelidikan) .....	173
4.	Courses attended /Technology acquisitions .....	173

## LIST OF TABLES

Table 1.1	Recommended antibiotic treatment for typhoid fever [adapted from (Bhutta, 2008)] .....	13
Table 2.1	Details of bacterial isolates used in evaluation of PCR assay using ST50 to identify <i>S. Typhi</i> .....	36
Table 2.2	Details of bacterial isolates from the stock culture collection of Institute for Research in Molecular Medicine (INFORMM) used in evaluation of PCR assay using ST50 gene in the presence of IAC to identify <i>S. Typhi</i> .....	37
Table 2.3	Sequences and maximum identical scores to the ST50 gene that showed significant alignments .....	40
Table 2.4	Evaluation study of the ST50 PCR assay with DNA from pure cultures of <i>S. Typhi</i> and other organisms .....	45
Table 2.5	Evaluation of PCR assay using ST50 gene with IAC performed with extracted DNA from pure cultures of <i>S. Typhi</i> and other organisms .....	46
Table 3.1	Results of PCR amplification using the ST50 gene on BACTEC blood culture samples .....	66
Table 3.2	Retrospective evaluation of the dry-reagent-based <i>S. Typhi</i> PCR assay .....	67
Table 4.1	Summary of stability testing of dry-reagent-based PCR at different temperatures and time points .....	81
Table 4.2	Summary of PCR results using three different thermal cyclers .....	84
Table 5.2.1	PCR results using DNA of spiked stool culture in the presence of PVP in the washing step .....	97
Table 5.2.2	PCR results using DNA of spiked stool culture in the presence of PVP in stool suspensions .....	98
Table 5.2.3	PCR results using DNA of spiked stool cultures without PVP .....	99
Table 5.3.1	Limit of detection (LOD) of PCR assay from stool and rectal swab culture at T0-T168 hours .....	109

Table 5.4.1	Results of PCR product obtained from DNA extracted from spiked stool cultures with various serial dilutions of overnight culture of <i>S. Typhi</i> .....	119
Table 5.4.2	Results of culture and PCR for stool swabs of confirmed typhoid carriers incubated 24 hours in Selenite F enrichment broth .....	121
Table A-1	List of chemicals, reagents and media used in this study (biological grade or analytical grade) .....	146
Table A-2	List of commercial kits and reagents used in this study .....	147
Table A-3	Primers for target gene and internal amplification control used in this study .....	149

## LIST OF FIGURES

Figure 1.1	Geographical distribution of typhoid fever .....	5
Figure 1.2	Distribution of typhoid fever, by age group, at various incidences	6
Figure 1.3	Incidence rate of typhoid fever per 100,000 population in Malaysia (2000-2005) (Jabatan Kesihatan Negeri Kelantan, 2005) .....	10
Figure 1.4	Number of typhoid cases in Kelantan, Malaysia (1994-2007) [adapted from (Mat Hussin, 2008)] .....	11
Figure 1.5	Research flow chart .....	26
Figure 2.1	Flow chart of the development of PCR test based on ST50 gene of <i>S. Typhi</i> .....	29
Figure 2.2	Flow chart of the development of PCR test based on ST50 gene with the presence of internal amplification control (IAC) .....	30
Figure 2.3	Profile of agarose gel electrophoresis showing amplified ST50 PCR products from <i>S. Typhi</i> DNA using annealing temperatures ranging from 50-70°C .....	41
Figure 2.4	Profile of agarose gel electrophoresis showing amplified product from a similar homologous gene of <i>S. Paratyphi A</i> DNA using annealing temperatures ranging from 50-70°C .....	42
Figure 2.5	Profile of agarose gel electrophoresis showing PCR products using different concentrations of MgCl <sub>2</sub> .....	43
Figure 2.6	Analytical sensitivity of the PCR assay with serially diluted DNA from <i>S. Typhi</i> ATCC 7251 .....	44
Figure 2.7	Profile of ST50 PCR assay with serially diluted IAC .....	47
Figure 2.8	Profile of ST50 PCR in the presence of IAC with different concentrations of MgCl <sub>2</sub> .....	48
Figure 2.9	Analytical sensitivity of ST50 PCR with the presence of IAC with serially diluted <i>S. Typhi</i> DNA .....	49
Figure 3.1	Flow chart of overall strategies of development and utilization of a dry-reagent-based PCR assay for the detection of <i>S. Typhi</i> in BACTEC blood cultures .....	55

Figure 3.2	Interpretation of amplified PCR products observed via agarose gel electrophoresis.....	60
Figure 3.3	Profile of agarose gel electrophoresis showing PCR results obtained using DNA extracted from BACTEC blood cultures ....	61
Figure 3.4	Profile of agarose gel electrophoresis showing PCR results obtained using DNA extracted from BACTEC blood cultures ....	62
Figure 3.5	Profile of agarose gel electrophoresis showing PCR results obtained using DNA extracted from BACTEC blood cultures ....	63
Figure 3.6	Profile of agarose gel electrophoresis showing PCR results obtained using diluted DNA extracted from BACTEC blood cultures .....	64
Figure 3.7	Profile of agarose gel electrophoresis showing PCR results obtained using diluted DNA extracted from BACTEC blood cultures .....	65
Figure 4.1(a)	Flow chart of the overall experiments to test the stability of the dry reagent based <i>S. Typhi</i> PCR kit .....	73
Figure 4.1(b)	Flow chart of the overall experiments to check the robustness of PCR using different thermal cyclers .....	74
Figure 4.2	Profile of agarose gel electrophoresis showing PCR products obtained when the dry PCR reagents were stored at 4°C .....	77
Figure 4.3	Profile of agarose gel electrophoresis showing PCR products obtained when the dry PCR reagents were stored at 25°C .....	78
Figure 4.4	Profile of agarose gel electrophoresis showing PCR products obtained when the dry PCR reagents were stored at 37°C .....	79
Figure 4.5	Profile of agarose gel electrophoresis showing PCR products obtained when the dry PCR reagents were stored at 42°C .....	80
Figure 4.6	Profile of agarose gel electrophoresis showing PCR products obtained using three different thermal cyclers .....	83
Figure 5.2	Optimization of DNA extraction from stool cultures and evaluation of the sensitivity and specificity of PCR assay from spiked stool cultures .....	91
Figure 5.2.1	Agarose gel electrophoresis of PCR results of DNA from stool spiked with <i>S. Typhi</i> and other bacteria .....	100

Figure 5.2.2	Agarose gel electrophoresis of PCR results of DNA from stool spiked with <i>S. Typhi</i> and other bacteria .....	101
Figure 5.3	Flow chart of comparative efficacy of PCR assay using stool and rectal swab cultures from T0 to T168 hours .....	105
Figure 5.4	Effect of enhancement procedures on stool sampling against sensitivity of the PCR assay .....	116
Figure A-1	Plasmid pVChMII Map: The insert containing <i>hemM</i> fragment generated by PCR is cloned into pCR2.1-TOPO .....	144



## LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS

Symbols/ Abbreviations	Definition
°C	Degree Celsius
µg	microgram
A <sub>260</sub>	Absorbance at 260 nm
A <sub>280</sub>	Absorbance at 280 nm
ATCC	American Type Culture Collection
ATP	Adenosine triphosphate
BLAST	Basic Local Alignment Search Tool
bp	Base pair
CaCl <sub>2</sub>	Calcium chloride
CFTR	Cyctic fibrosis transmembrane regulator
cfu	Colony forming unit
DNA	Deoxyribonucleic acid
dNTPs	Deoxyribonucleoside triphosphates
dTTP	2'-deoxythymidine 5'-triphosphate
EDTA	Ethylene diamine tetra acetic acid
ELISA	Enzyme linked immunosorbent assay
g	Gram
H <sub>2</sub> O	water
HCl	Hydrogen chloride
IgG	Immunoglobulin G
IgM	Immunoglobulin M
kb	Kilo base
KCl	Potassium chloride
KH <sub>2</sub> PO <sub>4</sub>	Potassium phosphate
KIA	Kligler Iron Agar
LPS	Lipopolysaccharide
MCS	Multiple cloning site
mg	milligram
MgCl <sub>2</sub>	Magnesium chloride
ml	milliliter

mM	millimolar
NaOH	Sodium hydroxide
ND	Not done
ng	nanogram
nm	nanometer
NPV	Negative predictive Value
OEP	Outer membrane efflux protein
OM	Outer membrane
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
pmol	picomole
PPV	Positive predictive Value
PVP	Polyvinyl pyrrolidone
SH	Shaking
SPS	Sodium polyanethosulfonate
ST	Static
T	Time
Ta	Annealing temperature
TAE	Tris-Acetate EDTA
TE	Tris EDTA
TMP-SMZ	Trimethoprim-sulphamethoxazole
TSI	Triple Sugar Iron
U	units
UDG	Uracil DNA glycosylase
USA	United States of America
UV	ultraviolet
V	volts
WHO	World Health Organization

**PENDEKATAN INOVATIF TERHADAP PEMBANGUNAN DAN  
PENGUNAAN KAEDAH DIAGNOSTIK BERASASKAN DNA BAGI  
*Salmonella Typhi***

**ABSTRAK**

Demam kepialu berpunca daripada *Salmonella Typhi* kekal sebagai masalah kesihatan di negara-negara kurang membangun dan sedang membangun. Kaedah pengkulturan konvensional dan ujian-ujian biokimia untuk mengenal pasti *S. Typhi* adalah sangat remeh dan memerlukan masa 2 hingga 7 hari untuk menghasilkan keputusan. Ujian alternatif berasaskan DNA yang pantas, sensitif dan mudah digunakan, perlu dibangunkan. Ke arah pembangunan ujian tersebut, gen yang mengkodkan protein spesifik 50 kDa daripada *S. Typhi* telah digunakan dan primer telah direka untuk mengamplifikasi produk DNA yang bersaiz 1238 bp.

Ujian PCR menggunakan primer tersebut telah dinilai terhadap DNA daripada 114 isolat bakteria *S. Typhi* dan 66 isolat bakteria bukan *S. Typhi*. Ujian ini menunjukkan 100% sensitiviti, spesifisiti, nilai ramalan positif (PPV) dan nilai ramalan negatif (NPV) 100%. Penilaian semula kaedah PCR ini telah dilakukan terhadap DNA daripada 25 isolat *S. Typhi* dan 25 isolat selain daripada *S. Typhi* dengan menggunakan kontrol amplifikasi dalaman (IAC). Keputusan sekali lagi menunjukkan nilai sensitiviti, spesifisiti, PPV and NPV 100% untuk mengenal pasti *S. Typhi*. Daripada keputusan ini adalah dirumuskan yang gen ST50 sesuai digunakan sebagai sasaran untuk mengenal pasti *S. Typhi* dengan menggunakan kaedah PCR.

Untuk mengatasi masalah ini, PCR biasa, satu campuran untuk *S. Typhi*

telah dibangunkan yang mengandungi campuran reagen PCR, primer untuk gen ST50, IAC dan larutan pewarna gel yang dibekukeringkan dalam sebuah tiub. Ini telah dilakukan dalam satu kaedah PCR reagen-formulasi-kering dua langkah untuk mengamplifikasi gen sasaran, 1238 bp dan 810 bp IAC daripada 73 sampel kultur darah BACTEC (33 sampel positif *S. Typhi* dan 40 sampel negatif *S. Typhi*). Nilai sensitiviti, spesifisiti, PPV dan nilai NPV adalah masing-masingnya 87.9%, 100%, 100% dan 90.9%. Keputusan yang diperolehi mencadangkan yang penggunaan ujian dua-langkah PCR-reagen formulasi kering boleh digunakan untuk mendiagnos demam kepialu akut.

Ujian PCR ini juga didapati teguh (robust) kerana dapat menghasilkan keputusan yang konsisten bila digunakan dengan tiga alat PCR berlainan jenama. Satu kajian telah dilakukan untuk mengkaji keupayaan/keberkesanan PCR reagen-formulasi-kering ini dalam keadaan berbeza penyimpanannya. Kit PCR ini telah didapati stabil pada suhu 4°C, 25°C dan 37°C selama enam bulan dan pada suhu 42°C selama sebulan. Kajian ini menunjukkan kebaikan dengan tidak memerlukan suhu penyimpanan -20°C seperti reagen PCR konvensional. Kelebihan seperti tahap sensitiviti yang tinggi dan spesifik, dan mudah digunakan, serta mesra pengguna membolehkan ujian PCR ini mudah diguna di negara-negara di mana kepialu adalah endemik.

Pengesanan *S. Typhi* untuk mengesan pembawa kepialu juga telah dikaji menggunakan kaedah PCR reagen-formulasi-kering ini. Tinja telah dicemarkan dengan 25 isolat *S. Typhi* dan 25 bukan *S. Typhi* dan dibiakkan dalam kaldu Selenite F selama 24 jam untuk meningkatkan bilangan bakteria ke tahap yang boleh dikesan.

DNA kemudiannya telah diasingkan dengan mendidihkan spesimen bersama PVP untuk mengurangkan perencat yang mengganggu. PCR telah berjaya dilakukan ke atas DNA yang diasingkan menggunakan kaedah pendidihan tanpa terdapat apa-apa petanda perencat DNA. Sensitiviti, spesifisiti, PPV dan NPV yang diperolehi adalah 100%.

Keberkesanan PCR telah dibandingkan ke atas penggunaan calitan rektal dengan calitan tinja dengan menentukan samada jangka masa inkubasi (T0-T168 jam) kedua-dua kultur tersebut mempengaruhi keberkesanannya. Keputusan ujian PCR menggunakan DNA yang diekstrak daripada kultur calitan rektal dan kultur tinja adalah setanding untuk sampel yang diinkubasi pada kedua-dua suhu (25°C dan 37°C) dalam keadaan statik ataupun goncangan pada 200 rpm dalam inkubator penggoncang. Kedua-dua sampel boleh digunakan untuk mengesan pembawa kepalu. Keputusan ujian PCR masih kekal positif bagi inkubasi sehingga 168 jam (7 hari). Kaedah PCR ini telah juga dibandingkan dengan satu kaedah kultur yang telah diubah suai untuk mengenal pasti *S. Typhi*. Dua daripada 16 spesimen telah didapati positif (12.5%). Namun demikian, bila dua kaedah ini dibandingkan, kaedah PCR reagen-formulasi-kering didapati lebih pantas sensitif dan mudah digunakan.

Sebagai kesimpulannya PCR reagen-formulasi-kering untuk *S. Typhi* boleh digunakan untuk mengamplifikasi gen *S. Typhi* daripada kultur darah pesakit kepalu; dan kultur tinja dan juga kultur calitan rektal pembawa kepalu.

# INNOVATIVE APPROACHES TOWARDS DEVELOPMENT AND UTILIZATION OF DNA DIAGNOSTICS FOR *Salmonella* Typhi

## ABSTRACT

Typhoid fever caused by *Salmonella* Typhi remains a public health problem in underdeveloped and developing countries. Conventional culture method and biochemical tests to identify *S. Typhi* lacked sensitivity, are laborious and produced results within 2 to 7 days. An alternative DNA test which is rapid, sensitive and user-friendly needs to be developed. Towards the development of such test, the gene encoding for the specific 50 kDa outer membrane protein of *S. Typhi* (ST50) was used and primers were designed to amplify this DNA product with a size of 1238 bp.

A PCR assay using such primers was evaluated against DNA extracted from pure cultures of 114 *S. Typhi* and 66 non-*S. Typhi* isolates. The assay showed sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100%. Re-evaluation of the PCR assay was performed with DNA of 25 *S. Typhi* and 25 non-*S. Typhi* isolates, with incorporation of an internal amplification control (IAC). The results again showed sensitivity, specificity, positive predictive value and negative predictive value of 100% in detecting *S. Typhi*. From the above results, it was concluded that ST50 gene can be successfully utilised as a target for the detection of *S. Typhi* by means of PCR.

To overcome limitations of conventional PCR, a ready-to-use PCR mix test for *S. Typhi* was designed comprising PCR reagents, primers of the ST50 gene of *S. Typhi*, a built-in IAC and gel loading dye mixed that was freeze-dried in a single

tube. This was used in a two-step dry-reagent-based PCR assay to amplify the 1238 bp target gene and the 810 bp IAC gene from 73 BACTEC blood culture broths (33 true positives for *S. Typhi* and 40 true negatives for non-*S. Typhi*). The sensitivity, specificity, PPV and NPV of the PCR assay were 87.9%, 100%, 100% and 90.9%, respectively. Results obtained suggested that the rapid two-step PCR test developed could be used for the rapid diagnosis of acute typhoid fever.

This PCR assay was also found to be robust and it showed consistent and reproducible results using three different thermal cyclers of different makes. A study was also performed to observe the efficiency of the dry-reagent-based PCR and the effect of storage conditions. The PCR kit was observed to be stable at 4°C, 25°C and 37°C for six months and 42°C for one month. The study revealed that this dry-reagent-based PCR kit has an advantage of obviating cold storage at -20°C of the conventional PCR reagents. The highly sensitive, specific and user friendly PCR assay can provide accessibility to countries where typhoid is highly endemic.

The detection of *S. Typhi* from stool specimens was attempted using this dry-reagent-based PCR to detect typhoid carriers. Stool was spiked with 25 *S. Typhi* and 25 non-*S. Typhi* inocula and cultured in Selenite F broth for 24 hours to increase the number of bacteria to a detectable. DNA was then extracted by boiling the specimen in the presence of PVP to reduce interfering inhibitors. The PCR successful results on the DNA extracted using the boiling method without any sign of inhibition. The sensitivity, specificity, PPV and NPV obtained were 100%.

The efficacy of rectal swab was then compared with stool swabs by determining the length of incubation time (T0-T168 hrs) of the stools and rectal swabs cultures for PCR to remain positive. PCR amplifications using the DNA extracted from rectal swab cultures were comparable to that of DNA extracted from stool cultures at both temperatures (25°C and 37°C) in either static or shaking condition at 200 rpm in an incubator shaker. Both samples can be used for the detection of typhoid carriers. The PCR results remained positive up to 168 hours (7 days) of incubation. The PCR assay was also compared with a modified culture method to detect *S. Typhi*. Two specimens from 16 specimens (12.5%) tested positive. Nevertheless, when the two methods were compared, the dry-reagent-based PCR was found to be more rapid, sensitive and easier to use.

In conclusion, the dry-reagent-based *S. Typhi* PCR test can be used to amplify *S. Typhi* gene from blood culture broths of typhoid patients and stool culture broths as well as rectal swab culture broths of typhoid carriers.



## CHAPTER 1

### General Introduction

#### 1.1 Introduction to typhoid fever

Typhoid fever is a global health problem. The real challenge is the difficulty in diagnosing because the clinical feature is confused with those of many other febrile infections (WHO, 2003). It is a systemic infection caused by *Salmonella enterica* serovar Typhi (*S. Typhi*), a Gram-negative organism, facultative anaerobic and flagellated bacilli from the family of Enterobacteriaceae (Bhan *et al.*, 2005). Typhoid patients usually present with a history of prolonged fever, headache, abdominal discomfort and general lethargy (House *et al.*, 2001). It is an enteric fever that starts as an infection of the gastrointestinal tract and develops into a systemic illness. The term enteric fever includes typhoid which is caused by *S. Typhi* and paratyphoid fever which is caused by *S. Paratyphi* A, B and C. The clinical symptoms of paratyphoid fever are usually less severe (Crum, 2003). Typically, typhoid fever passes through the following four phases: incubation, invasion, status period and evolution. The severity of the illness has been associated with the virulence of *S. Typhi* strain, immunocompetence, age, and nutritional status of patients (Crum, 2003). The infectious dose of *Salmonella* depends on the serovar, the bacterial strain, bacterial growth conditions and host susceptibility (Sussman, 2001). Infectious dose was determined to be between  $10^3$  and  $10^6$  organisms given orally (Bhan *et al.*, 2005). Ingestion of  $10^5$  organisms resulted in typhoid fever for up to 55% of the study volunteers (Guzman *et al.*, 2006).

## 1.2 Characteristics of *S. Typhi*


The genus *Salmonella* was named after the pathologist Salmon, who first isolated the organism from animal intestines. *Salmonella* is a member of family Enterobacteriaceae and contains two species, each of which contains multiples serotypes. The two species are *S. enterica* and *S. bongori*. *Salmonella enterica* subsp. *enterica* ser. Typhi is the complete name of the bacteria which causes typhoid fever and it was designated by Center of Disease Control (CDC) as *Salmonella* ser. Typhi (Brenner *et al.*, 2000) after the proposal to recognize the status *S. Typhi* together with *S. enteritidis* and *S. typhimurium* as species (Ezaki *et al.*, 2000) has been rejected. *S. Typhi* is rod-shaped with a length of 2-3  $\mu\text{m}$  and a diameter of 0.4-0.6  $\mu\text{m}$  (Le Monor, 1981). It is motile, with peritrichous flagella (H-d antigen), which is also encountered in 80 other bioserotypes of *Salmonella* (Ivanoff *et al.*, 1994). It is serologically positive for LPS antigens O9 and O12, protein flagellar antigen Hd and polysaccharide capsular antigen Vi (Agarwal *et al.*, 2004). Vi-antigen, is also found in *Citrobacter freundii*, *S. Paratyphi C*, and *S. Dublin* (Hashimoto *et al.*, 1995a).

Most *Salmonella* serotypes cannot be distinguished by biochemical reactions except *S. Typhi*. *S. Typhi* does possess some unique biochemical characteristics that will allow it to be differentiated via producing only trace amounts of hydrogen sulfide which is usually observed as a crescent-shaped wedge of black precipitate forming at the interface of the slant and butt in KIA or TSI media (Parry, 2006). In addition, *S. Typhi* are less active biochemically than the more common serotypes and is specifically negative for the following reactions: Simmon's citrate; ornithine decarboxylase; gas from glucose; fermentation of dulcitol, arabinose and rhamnose; and mucate and acetate utilization (Winn *et al.*, 2005).


### **1.3 Global epidemiology of typhoid fever**

Typhoid is estimated to have caused 21.6 million illnesses and 216,500 deaths globally (Crump *et al.*, 2004). The incidence of typhoid was high in South-Central Asia, Southeast Asia, and possibly southern Africa with more than 100 cases per 100,000 populations per year; but moderate in the rest of Asia, Africa, Latin America, and Oceania except for Australia and New Zealand with 10-1,000 cases per 100,000 populations; and low in the other parts of the world with less than 10 per 100,000 populations (Figure 1.1). Despite advances in technology and public health strategies, typhoid fever remains as a major cause of morbidity in the developing countries (Bhutta, 2008). Therefore, improvements in public health and sanitation are the most effective control methods against typhoid fever, and this requires long term investment in the infrastructure of the country (Cooke and Wain, 2004). The high incidence rate reported among young children less than five years old (Figure 1.2) may reflect high rate of transmission via food and water (Sinha *et al.*, 1999, Brooks *et al.*, 2006, Siddiqui *et al.*, 2006, Bhutta, 2008). The main reason was that antityphoid vaccine are currently being assessed only in children of school age and in older people, and the optimum age for immunization as part of public-health programs remains unclear (Sinha *et al.*, 1999). As mentioned by previous study, there are no proper plans for large scale vaccination programmes among infants and children (Bhutta, 2008). The interesting points highlighted in introducing typhoid vaccine into the paediatric vaccination schedule were the efficacy of the available vaccine and route of vaccination (Griffin, 1999, Sinha *et al.*, 1999). The efficacy of typhoid vaccine; Ty21a, which has been tested only in school children and adults is not suitable for large-scale use in developing countries for logistical and financial reasons (Simanjuntak *et al.*, 1991, Levine *et al.*, 1999). Therefore, a new vaccine

such as conjugates of the Vi polysaccharide which can be effective for young children should be developed (Sinha *et al.*, 1999). Recent emergence of drug resistance *S. Typhi* especially to first line antibiotics and quinolones has made the situation very difficult and expensive for health services to manage the disease (Cooke and Wain, 2004, Bhutta, 2008).



**Figure 1.1: Geographical distribution of typhoid fever (Crump *et al.*, 2004)**



**Figure 1.2:** Distribution of typhoid fever, by age group, at various incidences (Crump *et al.*, 2004)

#### **1.4 Epidemiology of typhoid in Malaysia**

Malaysia has been mapped as the region with high incidence rate of typhoid by Crump *et al.* (2004) but reports from Ministry of Health showed that the incidence rate was less than 5 per 100,000 populations (Kementerian Kesihatan Malaysia, 2006). According to the report of typhoid cases in Malaysia from 2000-2005, the highest incidence rate was reported in Kelantan followed by Sabah and Terengganu (Figure 1.3). Majority of the Kelantan people especially in rural areas use water from wells for drinking and other domestic purposes and do not have access to safe water from the treated water supply system (Kementerian Kesihatan Malaysia, 2006). The high incidence of typhoid fever in 2005 (Figure 1.4) might be related to the flood at the end of 2004 whereby the contaminated water overflowed into wells. In addition to the above scenario, food handlers, especially hawkers, and those involved in selling food at food stall were found to be lacking in knowledge, attitude and practice towards food-borne diseases and food safety. Their practices were poor in hand washing, personal hygiene and safety food handling (Zain and Naing, 2002). School-children were the most affected (Choo *et al.*, 1988, Yap and Puthuchery, 1998, Malik and Malik, 2001, Malik, 2002) and the contributing factors were related to unhygienic food handling practice followed by inadequate safe water supply and poor environmental sanitation (Meftahuddin, 2002). Despite being the state with the highest cases of typhoid, no data was reported for typhoid carriers. The National Antibiotic Surveillance showed that in the year 2000, 10.6% of *S. Typhi* isolates were resistant to ampicillin and 8.5% resistant to chloramphenicol (Lim, 2002). Resistance to ampicillin in Malaysia was transferred on a plasmid type IncH or IncI, and chloramphenicol was transmitted on an IncB plasmid (Ling and Chau, 1984). The ampicillin-resistant isolates harboured plasmid groups, IncA, IncC and IncC

suggest that these non-IncH plasmids were not stable in *S. Typhi* whereas IncH plasmids were stable and once acquired resulted in long term resistance (Wain and Kidgell, 2004).

### **1.5 Mode of transmission of typhoid**


Typhoid infection is transmitted via ingestion of food or water contaminated with feces. Ice cream has been recognized as a significant risk factor for the transmission of the disease. Shellfish taken from contaminated water, and raw fruit washed with contaminated water and vegetables fertilized with sewage, have been the source of past outbreaks. The highest incidence occurred where water supplies serving large populations are contaminated with feces (WHO, 2003). There was also case of sexual transmission of typhoid fever which may be acquired by means of oral and anal sex, as well as via food and drink (Reller *et al.*, 2003). The infectious dose is between  $10^3$  and  $10^6$  organisms given orally (Hornick *et al.*, 1970). The pathogenesis of typhoid fever starts with adherence to and invasion of gut epithelial cells, dissemination to systemic sites, and followed by survival and replication within host cells (House *et al.*, 2001). In addition, the products of certain strains of bacteria normally present in the intestinal microflora are able to trigger redistribution of cystic fibrosis transmembrane conductance regulator (CFTR) protein in epithelial cells. CFTR is used by *S. Typhi* as a receptor on epithelial cells which mediate the translocation of this microorganism to the gastric submucosa. Therefore, Serovar Typhi-epithelial cell adhesion and CFTR-dependent invasion by serovar Typhi of epithelial cells are increased due to commensal-mediated CFTR redistribution. As a result, commensal microorganisms present in the intestinal lumen could affect the efficiency of serovar Typhi invasion of intestinal mucosa and this could be a key




factor influencing host susceptibility to typhoid fever (Lyczak and Pier, 2002, Lyczak, 2003).

## **1.6 Treatment of typhoid fever**

*S. Typhi* isolates are still sensitive to the first-line drugs against typhoid such as chloramphenicol, ampicillin, amoxicillin and trimethoprim-sulfamethoxazole. Fluoroquinolones are more effective than the first-line drugs with excellent tissue penetration leading to the killing of *S. Typhi* in intracellular stationary stage as in monocyte/macrophages and hence achieve higher active drug levels in the gall bladder than other drugs (WHO, 2003). Studies have also shown that fluoroquinolones can achieve satisfactory cure rates (Van den Berg *et al.*, 1999, WHO, 2003) Table 1.1 shows the World Health Organization's recommendations for treating uncomplicated and severe cases of typhoid fever (WHO, 2003, Bhutta, 2008).



**Figure 1.3: Incidence rate of typhoid fever per 100, 000 population in Malaysia (2000-2005) (Jabatan Kesihatan Negeri Kelantan, 2005)**



**Figure 1.4: Number of typhoid cases in Kelantan, Malaysia (1994-2007)**  
 [adapted from (Mat Hussin, 2008)]

### **1.7 Management of typhoid carriers**

According to WHO, typhoid carriers should be treated with amoxicillin or ampicillin (100 mg per kg per day) plus probenecid (Benemid®) (1 g orally or 23 mg per kg for children) or TMP-SMZ (1600 to 800 mg twice daily) for six weeks and about 60% of persons treated with either regimen are expected to have negative cultures upon follow-up (WHO, 2003). Clearance of up to 80% of chronic carriers can be achieved with the administration of 750 mg of ciprofloxacin twice daily for 28 days or 400 mg of norfloxacin (Ferreccio *et al.*, 1988, Gotuzzo *et al.*, 1988). However, in cases of anatomic abnormality (eg. biliary or kidney stone), eradication of carrier cannot be achieved by antibiotic therapy alone but also requires surgical correction of abnormality. Cholecystectomy in individuals with gallstones or chronic cholecystitis eliminates the carrier state by 85% (Kalra *et al.*, 2003).

### **1.8 Definition of typhoid fever and typhoid carrier**

The definition of typhoid fever is divided into two groups by the World Health Organization (WHO, 2003); confirmed case and probable case of typhoid fever. Confirmed case of typhoid is defined as a patient with fever (38°C and above) that has lasted for at least three days, with a laboratory-confirmed positive culture (blood, bone marrow, bowel fluid) of *S. Typhi*, while a probable case of typhoid is defined as a patient with fever (38°C and above) that has lasted for at least three days, with a positive serodiagnosis or antigen detection test but without *S. Typhi* isolation. A chronic carrier is an individual who excretes *S. Typhi* in stools or urine for longer than one year after the onset of acute typhoid fever.

**Table 1.1: Recommended antibiotic treatment for typhoid fever [adapted from (Bhutta, 2008)]**

Susceptibility	Optimal treatment			Alternative effective treatment		
	Drug	Daily dose (mg/kg)	Course (days)	Drug	Daily dose (mg/kg)	Course (days)
<b>Uncomplicated typhoid fever</b>						
Fully sensitive	Fluoroquinolone (such as ofloxacin or ciprofloxacin)	15	5-7*	Chloramphenicol	50-75	14-21
				Amoxicillin	75-100	14
				TMP-SMX	8-40	14
Multidrug resistance	Fluoroquinolone <i>or</i>	15	5-7	Azithromycin	8-10	7
	Cefixime	15-20	7-14	Cefixime	15-20	7-14
Quinolone resistance†	Azithromycin <i>or</i>	8-10	7	Cefixime	20	7-14
	Ceftriaxone	75	10-14			
<b>Severe typhoid fever requiring parenteral treatment</b>						
Fully sensitive	Fluoroquinolone (such as ofloxacin)	15	10-14	Chloramphenicol	100	14-21
				Ampicillin	100	14
				TMP-SMX	8/40	14
Multidrug resistant	Fluoroquinolone	15	10-14	Ceftriaxone <i>or</i>	60	10-14
				Cefotaxime	80	
Quinolone resistant	Ceftriaxone <i>or</i>	60	10-14	Fluoroquinolone	20	14
	Cefotaxime	80				

\*Three day courses also effective, particularly so in epidemic containment.

†Optimum treatment for quinolone resistant typhoid fever has not been determined. Azithromycin, third generation cephalosporins, or a 10-14 day course of high dose fluoroquinolone is effective. Combinations of these are now being evaluated.

## **1.9 Diagnosis of typhoid fever**

### **1.9.1 Culture method**

Diagnosis of typhoid fever on clinical grounds is difficult because the signs and symptoms overlap with those of other common febrile illness (Crum, 2003). The standard method for diagnosing typhoid and paratyphoid fever is blood culture but the percentage of detection ranged from 40 to 70%. The detection method depends on the number of *S. Typhi* in the blood, the amount of blood used to culture, the type of culture medium used and the length of incubation period (Avendano *et al.*, 1986, Hoffman *et al.*, 1986). Failure to isolate the organism may be caused by several factors such as the limitations of laboratory media, the presence of antibiotics, the volume of specimen cultured or the time of collection whereby patients with a history of fever for seven to ten days would have positive blood culture less than seven days (WHO, 2003). *S. Typhi* can also be isolated from bone marrow, stool and intestinal secretion. A positive culture for *S. Typhi* is obtained in more than 90% of patients if culture is performed from all blood, bone marrow and intestinal secretions (Gilman *et al.*, 1975). According to WHO (2003), bone marrow aspirate culture is the gold standard for the diagnosis of typhoid fever and is particularly valuable for patients who have been previously treated, who have a long history of illness and for those with negative blood cultures with the recommended volume of blood. Furthermore, the viable counts of organisms in bone marrow were considerably less affected by antibiotic treatment than the quantitative blood counts. Despite successful treatment with fluoroquinolones which have excellent cellular penetration (Wain *et al.*, 2001), the bone marrow samples remained positive for up to five days or longer after starting the treatment (Gasem *et al.*, 1995). Isolation of the bacteria from the blood samples is still being used since bone marrow aspiration from patient is

difficult to obtain, relatively invasive, and of little use in public health setting (Bhutta, 2008). The problem with the culture method is time consuming because it takes two to seven days to produce results and it is laborious. Isolation of non-lactose fermenting colonies from agar plates need to be identified by biochemical test and serotyping and these procedures are expensive for developing countries (Haque *et al.*, 1999, WHO, 2003). The development of a rapid and sensitive diagnostic method for typhoid, therefore, is of practical importance in endemic areas.

### **1.9.2 Felix-Widal test**

The conventional serological method for typhoid diagnosis, Widal test; which measures agglutinating antibody, is not reliable using single titres in endemic areas (Levine *et al.*, 1978). However, this test continues to be used since it is simple, cheap and requires no instrumentation. The demonstration of a four-fold rise in titre of antibodies to *S. Typhi* suggests typhoid fever but is invariably too late to help clinical decision-making (Parry, 2005). The method also showed the difficulty in determining an appropriate cut-off for positive results since it varies between areas (Clegg *et al.*, 1994). The Widal test uses a crude assay method to detect antibodies by their ability to agglutinate whole bacterial cells against O and H antigens in test tubes. *S. Typhi* shares O and H antigens with other *Salmonella* serotypes and has cross-reacting epitopes with other *Enterobacteriaceae*, and this can lead to false positive results (WHO, 2003). The test also has low sensitivity since it can be negative in up to 30% of culture positive samples (WHO, 2003). New tests are currently being developed to detect acute typhoid fever.

### **1.9.3 Tubex test**

The TUBEX test which uses a simple one step procedure is more rapid and accurate than the Widal. This test detects anti-Salmonella O9 (both IgM and IgG) antibodies in patients by inhibiting the binding between anti-O9 IgM monoclonal antibody conjugated to colored latex particles and *S. Typhi* lipopolysaccharide (LPS) conjugated to magnetic latex particles (Lim *et al.*, 1998, Mabey *et al.*, 2004). In other words, TUBEX combines the antigen *S. Typhi* LPS as detector with a specific monoclonal antibody directed against O9 antigen as indicator. There are two disadvantages of TUBEX. This include, first, the difficulty in interpreting the results from haemolysed samples because it uses a colorimetric reaction. Secondly, the analytical sensitivity is very low and thus, early cases may be missed although both clinical sensitivity and specificity were 100% (Lim *et al.*, 1998). However, these happened before the kit was commercially available. Due to the similarities in O9 antigen in both *S. Typhi* and group D (*S. Enteritidis*) which contains a sugar,  $\alpha$ -D-tyvelose, TUBEX produced false positive results in person with recent *S. Enteritidis* infection (Oracz *et al.*, 2003). Evaluation of TUBEX for detection of typhoid fever in Vietnam showed sensitivity and specificity of 78% and 89% respectively (Olsen *et al.*, 2004). Previous study done in the Philippines showed a sensitivity of 94.7%, specificity of 80.4%, PPV of 78% and NPV of 95.% (Kawano *et al.*, 2007). The TUBEX need to be evaluated in larger trials in community settings (Bhutta, 2008).

### **1.9.4 TYPHIDOT and TYPHIDOT –M**

The other test available in the market is the *TYPHIDOT* which detects the IgM and IgG antibodies against a 50 kDa protein of *S. Typhi*. The 50 kDa protein is a specific



protein on the outer membrane of *S. Typhi* (Ismail *et al.*, 1991a). The dot enzyme immunoassay method developed using the 50 kDa antigen showed a sensitivity of greater than 90% and specificity of 75% (Choo *et al.*, 1994). *TYPHIDOT-M* was developed to remove total IgG in order to detect for the presence of IgM especially for the convalescence or possible acute relapse cases in which IgG was boosted by secondary immune response (Ismail *et al.*, 1998). The *TYPHIDOT-M* detects for the presence of IgM alone with a sensitivity of 92% and specificity of 100% among the outpatients of all ages. The test is useful in high endemic areas since it can differentiate convalescence and new cases. Studies showed that the sensitivity of *TYPHIDOT-M* was higher than *TYPHIDOT* but other evaluations suggested that the performance may not be as robust in community setting as in the hospital (Bhutta, 2008).

### **1.10 Diagnosis of typhoid carriers**

Typhoid carriers were confirmed by isolation of *S. Typhi* from stool or rectal swab cultures and identified via biochemical tests (WHO, 2003) but these methods are costly, laborious and tedious. Three stool samples taken at different times are required and many of these cultures have to be obtained from individuals who are elderly, poorly educated, fail to understand the implications of their condition and may consequently be suspicious and uncooperative (Nolan *et al.*, 1980a, Nolan *et al.*, 1981). Knowing the difficulties to obtain faecal samples and perform the test, a reliable assay should be developed. An alternative serological test using crude Vi antigen from *Citrobacter freundii* was developed but this assay was not specific enough to be applied as a routine diagnostic tool for the detection of typhoid carriers. It was then revised using purified Vi antigen and specificity was found to increase

but the sensitivity remained similar to the traditional method using crude Vi antigen (Nolan *et al.*, 1980a).

*S. Typhi* is distinguished from other salmonellae by its metabolic characteristics, its capsular polysaccharide (Vi antigen), its inability to colonize a similar disease in other animal species, and its ability to establish a chronic infection in their gall bladder in about 2-5% of individuals after an acute infection. The Vi antigen is both the virulence factor and protective antigen of *S. Typhi*. Stools of suspected typhoid carriers were cultured and the presence of the Vi antigen on these isolates were confirmed by the antiserum agar technique (Nolan *et al.*, 1980b).

Using Vi antigen as a marker for detection of typhoid carriers, serological test started with agglutination assay followed by hemagglutination of erythrocytes coated with purified Vi and other method measuring the Vi antibodies (Landy and Lamb, 1951, Lanata *et al.*, 1983) including counterimmunoelectrophoresis (Chau and Tsang, 1982, Sarasombath *et al.*, 1983), and ELISA (Engleberg *et al.*, 1983). A radioimmunoassay which is simple, rapid, and quantitative was used to identify carrier facilitated by measurement of serum Vi antibodies (Lin *et al.*, 1988). No test for detection of typhoid carriers is available in the market. Since the world is moving towards the development of molecular based diagnostics, it is thus necessary to identify typhoid carriers with a more sensitive and specific molecular method to eradicate carriers.

## **1.11 Research background and rationale of the study**

### **1.11.1 History of 50 kDa outer membrane protein of *Salmonella* Typhi**

A 50 kDa outer membrane protein of *S. Typhi* was found to be antigenically specific (Ismail *et al.*, 1991a) and a dot enzyme immunosorbent assay was developed by the group (Ismail *et al.*, 1991b) which detects the presence of specific IgM and IgG antibodies in typhoid patients namely, *TYPHIDOT*. The assay was developed in order to have a rapid, easy to perform and inexpensive test for the early and accurate diagnosis of typhoid fever, as compared to the gold standard culture method and the Widal test which is difficult to interpret. The dot enzyme immunoassay (EIA) using this outer membrane protein was found to be sensitive and specific as reported by Choo *et al.* (1994, 1997). The test was then improved by the development of a new kit, *TYPHIDOT-M* which detects the presence of only IgM by removing total IgG to differentiate between new acute typhoid fever and convalescence cases (Ismail *et al.*, 1998). Studies using *TYPHIDOT* and *TYPHIDOT-M* was performed on sera from febrile Malaysian children suggested that the tests was rapid and reliable in a high endemic area with 90.3% and 93.1% sensitivity respectively and combination of both tests gave a higher sensitivity of 95.2% and specificity of 87.5% (Choo *et al.*, 1999). The assay was claimed and proven to be superior to Widal test shown by the higher sensitivity (85-94%) and specificity (77-89%) in a study with a consecutive group of children with suspected typhoid fever in Karachi, Pakistan (Bhutta and Mansurali, 1999). Similarly, other studies also showed that the assay was highly sensitive (78-98%) and specific (68-98.8%) (Bhutta and Mansurali, 1999, Olsen *et al.*, 2004). Since 1994, *TYPHIDOT* has been used in diagnosing typhoid fever in several countries including Pakistan and Philippines. The kit received recognition by the Centres for Disease Control and Prevention (CDC), Atlanta in 2002

(www.mbdr.com.my). The gene (ST50 gene:1476 bp) which encodes the 50 kDa outer membrane protein of *S. Typhi* was submitted to Genbank with accession number BD079162 (Ismail *et al.*, 2002) and was patented by Universiti Sains Malaysia (Ismail *et al.*, 2006).

### **1.11.2 Development of molecular methods for detection of *S. Typhi* from blood, stool and rectal swab**

Molecular diagnostics are revolutionizing the clinical practice of infectious disease (Yang and Rothman, 2004). In fact, molecular testing has been heralded as the “diagnostic tool for the new millennium” whose ultimate potential could render traditional hospital laboratories obsolete (Pitt and Saunders, 2000). Previous studies reported several approaches for detection of *S. Typhi* using DNA probe and polymerase chain reaction (PCR). Different *S. Typhi* genes were used but the tests needed to be improved. The PCR technique can detect small amount of DNA by enzymatic amplification. A DNA probe against the Vi antigen was used to detect *S. Typhi* in the blood of patients with typhoid fever (Rubin *et al.*, 1989). Problems with the use of a DNA probe in blood samples include low bacteraemia among typhoid patients and the sensitivity of the probe. The Vi probe detected typhoid DNA in 13 out of 32 (sensitivity of 40.6%) patients using equivalent of 2.5 ml of blood for DNA probing whereas the blood culture was positive in 17 out of 32 patients (sensitivity of 53.1%) when culturing eight ml of blood. The Vi probe also showed positive in five of 48 (10%) culture negative patients. Furthermore, the time frame for detection of the Vi DNA probe was about three days.

A PCR-based test using flagellin gene was developed to detect *S. Typhi* in the blood of typhoid patients (Song *et al.*, 1993). The problem with the method was that the first PCR was not able to detect all the 12 blood samples from patients with culture-confirmed typhoid fever. Only after performing the nested PCR, amplifications were seen in 11 of 12 (sensitivity of 91.6%) specimens on the agarose gel. Southern blot hybridization with a <sup>32</sup>P-labeled internal probe showed the same pattern compared to agarose gel. The first PCR detected at least 10<sup>6</sup> bacteria whereas the more sensitive nested PCR detected a minimum of ten bacteria. The procedure of the first PCR and nested PCR took seven hours excluding the DNA extraction and gel electrophoresis or southern blot hybridization procedures.

The same primers from flagellin gene were used to develop PCR and nested PCR assay in Pakistan and India (Haque *et al.*, 1999, Kumar *et al.*, 2002). The study by Haque *et al.* (1999) showed a sensitivity of 71.9% compared to 34.1% with blood culture and 36.5% with Widal test using 25 healthy individuals and 82 typhoid patients. Although the PCR method gives the highest sensitivity rate compared to blood culture and Widal test, the percentage was unimpressive as it was less than 80% detection rate. Other study showed the sensitivity of 100% but was performed with only 20 blood culture positive cases (Kumar *et al.*, 2002). Out of 20 blood culture negative cases tested, 12 (60%) were positive with PCR.

Previous prospective study showed an attempt to detect *S. Typhi* by nested PCR to amplify unique sequences in the region VI of the flagellin gene using blood, urine and stool samples from suspected typhoid patients revealed a sensitivity of 84.5%, 69.3% and 46.9% respectively (Song *et al.*, 1993). In comparison, the sensitivities of

blood culture and Widal tests were 61.8% and 39.0% respectively (Hatta and Smits, 2007). This finding proved that the PCR is the best choice for diagnosis of typhoid fever but it needs to be improved. Furthermore, it is not yet available in the market. Indeed, PCR should be utilised to detect possible carriers to prevent any typhoid outbreak in the near future.

Hence, there is a need to develop a rapid and sensitive molecular method for effective management of both typhoid fever and typhoid carriers. The diagnosis of typhoid fever and typhoid carriers require accurate identification of *S. Typhi* in clinical samples by DNA based, instead of antibody detection because it shows the presence of bacteria rather than the antibody released due to past exposure to the bacteria. The aim of the present study is to develop an ideal diagnostic test with the following characteristics: (1) affordable by those at risk of infection, (2) high sensitivity and specificity, (3) user-friendly, (4) easy to perform, (5) rapid, (6) do not require refrigerated or frozen storage and, (7) contain built-in internal amplification control (IAC).

Most molecular assays rely on nucleic acid extraction, amplification and detection of an amplified product. Several approaches were performed to ensure the success of the test including:-

1. The incubation of samples in a suitable media to allow bacteria to multiply until a detectable level for single PCR to be amplified.
2. A simple boiling method for DNA extraction from BACTEC blood culture broths, rectal swab and stool culture broths that will reduce inhibitors.
3. The development of a single PCR test instead of nested PCR test which is

4. The use of built-in IAC to validate the negative PCR results whether it is truly negative or false negative due to inhibition.
5. The development of a robust *S. Typhi* dry-reagent-based PCR which is stable at room temperature or higher.

Therefore, the objectives of this study will be discussed in 1.12.

### **1.12 Objectives of the study**

#### **General objective:**

The aim of this research project is to develop a rapid and sensitive dry-reagent-based PCR to detect typhoid fever and typhoid carriers coupled with improvements in the culture method.

#### **Specific objectives:**

The research objectives are divided into four phases as shown in the research flow chart (Figure 1.5):

#### **Phase 1: Development of PCR assay using gene encoding for 50 kDa outer membrane protein of *Salmonella Typhi***

1. To design primers using the gene encoding for the 50 kDa outer membrane of *S. Typhi*.
2. To optimize a PCR assay using DNA extracted from pure cultures.
3. To evaluate the sensitivity and specificity of the PCR assay using DNA extracted from *S. Typhi* and other isolates.

**Phase 2: Development and utilization of a dry-reagent-based PCR assay for the detection of *S. Typhi***

4. To develop a dry-reagent-based PCR assay for *S. Typhi*.
5. To evaluate the sensitivity and specificity of the PCR assay using extracted DNA from BACTEC blood cultures.

**Phase 3: Stability testing and comparison of reproducibility and consistency of the dry-reagent-based PCR**

6. To check the stability of the dry-reagent-based PCR in four different storage temperatures.
7. To compare the reproducibility and consistency of the dry-reagent-based PCR using different thermal cyclers.

**Phase 4: Evaluation of dry-reagent-based PCR for the detection of *S. Typhi* in stool and rectal swab culture specimens**

8. Optimization of DNA extraction from stool cultures and evaluation of the sensitivity and specificity of PCR from spiked stool cultures
  - a. To optimize the utilization of polyvinyl pyrrolidone (PVP) procedures for DNA extraction from spiked stool cultures.
  - b. To evaluate the sensitivity and specificity of the dry-reagent-based PCR using DNA extracted from stool cultures spiked with *S. Typhi*.
9. Comparative efficacies of PCR assay using stool and rectal swab cultures
  - a. To compare the effectiveness of dry-reagent-based PCR assay using stool and rectal swab cultures.